145525-41-3
145525-41-3
Chemical Structure
Mitiglinide calcium
Synonym(s): KAD-1229 anhydrous; S21403 anhydrous
- CAS No.: 145525-41-3
- Formula:C19H24NO3 . 1/2 Ca
- Molecular Weight:334.44
SMILES: O=C([O-])[C@H](CC(N1C[C@](CCCC2)([H])[C@]2([H])C1)=O)CC3=CC=CC=C3.[0.5Ca2+]
Biological Activity: Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes[1][2].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mitiglinide calcium | 98.82% | Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mitiglinide calcium (Standard) | ≥98% | Mitiglinide (calcium) (Standard) is the analytical standard of Mitiglinide (calcium). This product is intended for research and analytical applications. Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(2R)-Mitiglinide-d10 calcium | (2R)-Mitiglinide-d10 calcium (KAD-1229-d10 Calcium ) is the deuterium labeled (2R)-Mitiglinide calcium. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25. [Content Brief]
- [2]. Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29(5-6):423-7. [Content Brief]
